On May 8, 2014 the U.S. Food and Drug Administration approved the formidable cardiovascular drug Vorapaxar. Known as the brand name Zontivity, which is marketed by Merck, this pivotal medication has proven to be outstanding in clinical trials. In three short years of study Vorapaxar demonstrated its ability to successfully reduce the rate of death[…]
FDA Approves Pivotal Cardiovascular Drug Vorapaxar
Antithrombotic, Cardiovascular Agent, Drug Research & Development API, FDA Approved 2014 Tags: Drug Administration May 15, 2014
FDA Approves Bosutinib for Chronic Myelogenous Leukemia
Chemotherapeutic / Anti-Neoplastic, FDA Approval News Tags: Drug Administrationimatinibleukemia Sep 05, 2012
The U.S. Food and Drug Administration today approved Bosutinib CAS# 380843-75-4, marketed under the trade name Bosulif, to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. An estimated 5,430 men and women will be diagnosed with CML in 2012. Most people with CML have a genetic mutation,[…]
Pixantrone Maleate as a New Treatment for Patients with Non-Hodgkin's Lymphoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AnthracyclinesDrug AdministrationRituximab Feb 13, 2012
Pixantrone maleate, CAS Number 146675-97-8, is an anthracenedione anthracycline derivative, developed by Cell Therapeutics Incorporated. Pixantrone maleate is used for treatment of patients with non-Hodgkin’s lymphoma. LGM Pharma is a provider of pixantrone maleate for research and development purposes. As a promising treatment for aggressive non-Hodgkin’s lymphoma, pixantrone maleate is well tolerated when substituted for[…]
Liraglutide diabetes control is proven and leads to weight loss
Anti-Diabetic, Drug Research & Development API Tags: anti-diabeticDrug AdministrationLiraglutidetype 2 Diabetes Dec 28, 2010
Liraglutide Diabetes Control Liraglutide is a newly developed drug that is used to control the levels of blood glucose in patients suffering from type 2 Diabetes. In January 2010, the US Food and Drug Administration approved this drug for the treatment of patients with diabetes. Liraglutide was approved by the European Medicines Agency (EMEA) in[…]
Eltrombopag brings feasible relief to Chronic ITP patients
Drug Research & Development API Tags: Drug Administration Dec 28, 2010
Eltrombopag is an effective drug that can help patients suffering from thrombocytopenia. This disease occurs when the percentage of platelets in the patient’s blood decreases to abnormally low levels. The molecule of Eltrombopag acts as an agonist for TpoR receptor and it stimulates the thrombopoietin hormone which helps to increase the presence of platelets in[…]
Dextromethorphan Hydrobromide Therapy and Usage
Drug Research & Development API, OTC and Compounding Product Tags: Drug Administrationmultiple sclerosis Dec 14, 2010
Dextromethorphan Hydrobromide is a well known cough suppressant drug. During a research study jointly funded by the CIA and the US Navy, Dextromethorphan Hbr was established as a non-addictive substitute for Codeine, a common cough depressant. Codeine is an analgesic, which is addictive in nature. In 1958, the U.S. Food and Drug Administration approved this[…]
LGM Pharma Supplies Ingredients for Several Anti-Obesity Drugs
Anti-Migraine, Anti-Obesity Product, Bulk Active Ingredient, Compounding API, Drug Research & Development API Tags: Drug AdministrationlorcaserinObesityTopiramate Aug 31, 2010
LGM Pharma supplies Topiramate, Bupropion, Naltrexone and Lorcaserin – Active Pharmaceutical Ingredients (APIs) used to treat obesity.
